Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $58.85M fell 4.5% year over year, behind the +3.7% change in trailing-twelve-month research & development. Sequentially, it fell 25.2% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.
Context
- Research & development amounted to 150.1% of revenue in FY2025, down 870.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -4.5% toward the trailing-twelve-month pace of +3.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 258.78M USD
- Year-over-year change
- +7.1%
- 4-year CAGR
- +30.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 258.78M | +7.1% |
| FY2024 | 2024-12-31 | 241.65M | +48.2% |
| FY2023 | 2023-12-31 | 163.03M | +37.6% |
| FY2022 | 2022-12-31 | 118.5M | +34.3% |
| FY2021 | 2021-12-31 | 88.25M | — |
Research & Development vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 research & development of $255.99M is the 4th highest of the 11 companies compared; the peer median is $179.37M.
- Its year-over-year change of +3.7% is the 6th highest of 11, against a peer median of +6.4%.
- Research & development amounts to 117.9% of revenue for SNDX, versus a peer median of 194.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.51B | +1655.5% | -13.1% | 942.7% | |
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Mar 2026 | $255.99M | +3.7% | +29.7% | 117.9% | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Dec 2025 | $223.39M | +26.2% | +32.9% | — | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $69.1M | -13.8% | -14.9% | 194.4% | |
| LTM Mar 2026 | $66.71M | -38.5% | -7.9% | — | |
| Peer median (excluding SNDX) | $179.37M | +6.4% | +7.8% | 194.4% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.71M | 0 | 0 | 23.68M | 172.35M |
| Cost of Revenue | 0 | 0 | 0 | 826K | 6.97M |
| Gross Profit | 139.71M | 0 | 0 | 22.85M | 165.38M |
| Gross Margin | 100.0% | — | — | 96.5% | 96.0% |
| Research & Development | 88.25M | 118.5M | 163.03M | 241.65M | 258.78M |
| Selling, General & Admin | 25.24M | 33.26M | 66.92M | 120.88M | 179.68M |
| Operating Expenses | 113.49M | 151.76M | 229.95M | 362.53M | 438.47M |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| EBITDA | 26.87M | (146.17M) | (209.14M) | (313.82M) | (251.63M) |
| EBITDA Margin | 19.2% | — | — | -1325.3% | -146.0% |
| Operating Income | 26.22M | (151.76M) | (229.95M) | (339.67M) | (273.08M) |
| Operating Margin | 18.8% | — | — | -1434.4% | -158.4% |
| Interest Income | 403K | 5.87M | 21.16M | 26.09M | 22.73M |
| Interest Expense | 1.9M | 3.14M | 208K | 4.93M | 33.79M |
| Other Income / Expenses | (1.29M) | 2.42M | 20.59M | 20.91M | (12.34M) |
| Income Before Tax | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Pre-Tax Margin | 17.8% | — | — | -1346.1% | -165.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Net Margin | 17.8% | — | — | -1346.1% | -165.6% |
| EPS (Basic) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| EPS (Diluted) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| Weighted Avg Shares | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M |
| Weighted Avg Shares (Diluted) | 52.06M | 60.76M | 70.37M | 85.62M | 86.63M |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.